Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: A randomized controlled trial

BMC Nephrology

Volumn 9, Issue 1, 2008, Pages

  Johnson, David Wayne ^a,b   Hawley, Carmel Mary ^a,b   Rosser, Brenda ^a   Beller, Elaine ^a   Thompson, Charles ^a   Fassett, Robert G ^a,c   Ferrari, Paolo ^a,d   MacDonald, Stephen ^a,e   Pedagogos, Eugenie ^a,f   Cass, Alan ^a,g  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c Launceston General   (Australia)

^d FREMANTLE HOSPITAL   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g GEORGE INSTITUTE FOR INTERNATIONAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ASCORBIC ACID; ERYTHROPOIETIN; FOLIC ACID; HEMOGLOBIN; IRON; MELATONIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PENTOXIFYLLINE; PLACEBO; VITAMIN B GROUP; ANTIANEMIC AGENT; DRUG DERIVATIVE;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; HEMODIALYSIS PATIENT; HUMAN; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; BLOOD CELL COUNT; CHRONIC KIDNEY FAILURE; DRUG EFFECT; DRUG RESISTANCE; ERYTHROPOIESIS; METHODOLOGY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SELECTION; SAMPLE SIZE; STATISTICS;

ADULT; ANEMIA; BLOOD CELL COUNT; BLOOD TRANSFUSION; DOUBLE-BLIND METHOD; DRUG RESISTANCE; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PENTOXIFYLLINE; RESEARCH DESIGN; SAMPLE SIZE;

EID: 50249092167     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-9-8     Document Type: Article

References (28)

1. Erythropoietin in chronic renal failure. F Valderrabano, Kidney Int 1996 50 1373 1391 10.1038/ki.1996.452 8887302
2. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). RL Benz MR Pressman ET Hovick DD Peterson, Am J Kidney Dis 1999 34 1089 1095 10.1016/S0272-6386(99) 70015-6 10585319
3. Strategies for iron supplementation: oral versus intravenous. IC Macdougall, Kidney Int 1999 55 Suppl 69 S61 6 10.1046/j.1523-1755.1999.055Suppl. 69061.x
4. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. IC Macdougall AC Cooper, Nephrol Dial Transplant 2002 17 Suppl 11 39 43 12386257
5. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. AC Cooper A Mikhail MW Lethbridge DM Kemeny IC Macdougall, J Am Soc Nephrol 2003 14 1776 1784 10.1097/01.ASN.0000071514.36428. 61 12819237
6. Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. JE Frampton RN Brogden, Drugs Aging 1995 7 480 503 10.2165/00002512-199507060-00007 8601054
7. Oxpentifylline and cetiedil citrate improve deformability of dehydrated sickle cells. J Stuart PC Stone YY Bilto AJ Keidan, J Clin Pathol 1987 40 1182 1186 3119675 10.1136/jcp.40.10.1182
8. Regulatory effects of pentoxifylline on T-helper cell-derived cytokine production in human blood cells. N Benbernou S Esnault G Potron M Guenounou, J Cardiovasc Pharmacol 1995 25 Suppl 2 S75 S79 8699867
9. Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Bienvenu C Doche MC Gutowski M Lenoble A Lepape JP Perdrix, J Cardiovasc Pharmacol 1995 25 Suppl 2 S80 S84 8699868
10. Pentoxifylline. A hydroxyl radical scavenger. JP Freitas PM Filipe, Biol Trace Elem Res 1995 47 307 311 10.1007/BF02790131 7779563
11. Effect of pentoxifylline on apoptosis of cultured cells. F Belloc C Jaloustre P Dumain F Lacombe M Lenoble MR Boisseau, J Cardiovasc Pharmacol 1995 25 Suppl 2 S71 S74 8699866
12. Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. J Semmler U Gebert T Eisenhut J Moeller MM Schonharting A Allera S Endres, Immunology 1993 78 520 525 8388363
13. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. A Cooper A Mikhail MW Lethbridge DM Kemeny IC Macdougall, J Am Soc Nephrol 2004 15 1877 1882 10.1097/01.ASN.0000131523.17045.56 15213276
14. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. JF Navarro C Mora J Garcia A Rivero M Macia E Gallego ML Mendez J Chahin, Scand J Urol Nephrol 1999 33 121 125 10.1080/003655999750016113 10360454
15. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. E Nemeth EV Valore M Territo G Schiller A Lichtenstein T Ganz, Blood 2003 101 2461 2463 10.1182/blood-2002-10-3235 12433676
16. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. E Nemeth S Rivera V Gabayan C Keller S Taudorf BK Pedersen T Ganz, J Clin Invest 2004 113 1271 1276 15124018
17. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. CH Park EV Valore AJ Waring T Ganz, J Biol Chem 2001 276 7806 7810 10.1074/jbc.M008922200 11113131
18. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. P Lee H Peng T Gelbart L Wang E Beutler, Proc Natl Acad Sci U S A 2005 102 1906 1910 15684062 10.1073/pnas.0409808102
19. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. E Nemeth MS Tuttle J Powelson MB Vaughn A Donovan DM Ward T Ganz J Kaplan, Science 2004 306 2090 2093 10.1126/science.1104742 15514116
20. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. M Girndt H Kohler E Schiedhelm-Weick JF Schlaak KH Meyer zum Buschenfelde B Fleischer, Kidney Int 1995 47 559 565 10.1038/ki.1995.70 7723241
21. Associations between circulating inflammatory markers and residual renal function in CRF patients. R Pecoits-Filho O Heimburger P Barany M Suliman I Fehrman-Ekholm B Lindholm P Stenvinkel, Am J Kidney Dis 2003 41 1212 1218 10.1016/S0272-6386(03)00353-6 12776273
22. Prohepcidin accumulates in renal insufficiency. YE Taes B Wuyts JR Boelaert AS De Vriese JR Delanghe, Clin Chem Lab Med 2004 42 387 389 10.1515/CCLM.2004.069 15147148
23. Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. H Kulaksiz SG Gehrke A Janetzko D Rost T Bruckner B Kallinowski W Stremmel, Gut 2004 53 735 743 15082594 10.1136/gut.2003.022863
24. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. PJ Barnes M Karin, N Engl J Med 1997 336 1066 1071 10.1056/NEJM199704103361506 9091804
25. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. P Neuner G Klosner E Schauer M Pourmojib W Macheiner C Grunwald R Knobler A Schwarz TA Luger T Schwarz, Immunology 1994 83 262 267 7835945
26. Plasma levels of TNF and IL-6 following induction of acute pancreatitis and pentoxifylline treatment in rats. J Marton G Farkas Z Nagy T Takacs J Varga Z Szasz A Balogh J Lonovics, Acta Chir Hung 1997 36 223 225 9408354
27. Pentoxifylline diminished acetaldehyde-induced collagen production in hepatic stellate cells by decreasing interleukin-6 expression. E Hernandez A Correa L Bucio V Souza D Kershenobich MC Gutierrez-Ruiz, Pharmacol Res 2002 46 435 443 10.1016/S1043661802002025 12419648
28. Anemia in hemodialysis patients: variables affecting this outcome predictor. F Madore EG Lowrie C Brugnara NL Lew JM Lazarus K Bridges WF Owen, J Am Soc Nephrol 1997 8 1921 1929 9402095